Show simple item record

dc.contributor.advisor王志强
dc.contributor.author梅佳
dc.date.accessioned2016-02-23T01:05:31Z
dc.date.available2016-02-23T01:05:31Z
dc.date.issued2015-07-08 17:35:37.0
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/95636
dc.description.abstract自20世纪90年代以来,全球医药行业就掀起了并购、重组浪潮。目前位列财富500强制药行业榜单前十位的医药公司如强生、诺华、辉瑞等无一例外都是经过了一系列的兼并重组,才发展成为了当今的跨国医药巨头。 任何企业想要做大做强必然依靠内部增长和外部并购两条路。从行业背景分析,医药行业具有生产投入大、投资风险高、科技含量高、研发时间长的特点,相比内部的、有机的增长,兼并收购可以在短期内迅速扩大生产规模和销售网络,增加市场份额,提高竞争力,减少新药开发风险,提升公司的规模和实力,从而优化整个产业的效益。从国家政策面分析,国家一直以来都大力支持医药行业的并购重组工作。在医药工业“一二五”发展规划中,鼓励优...
dc.description.abstractSince 1990's, a wave of mergers and acquisitions (M&A) was set off in the global medical industry. Such as Glaxo-SmithKline Beecham, Pfizer-Wyeth, Roche-Genentech, Johnson & Johnson-Synthes, Medtronic-Covidien, etc. All of these multinational medical companies have experienced different scale of M&A, so as to become today's giants. There are two ways to promote expansion of enterprise, one is mer...
dc.language.isozh_CN
dc.relation.urihttps://catalog.xmu.edu.cn/opac/openlink.php?strText=46220&doctype=ALL&strSearchType=callno
dc.source.urihttps://etd.xmu.edu.cn/detail.asp?serial=50406
dc.subject兼并收购
dc.subject强生
dc.subject医药企业
dc.subjectM&A
dc.subjectJohnson & Johnson
dc.subjectMedical company
dc.title强生医疗收购辛迪斯的案例分析
dc.title.alternativeCase study of J&J's acquisition of Synthes
dc.typethesis
dc.date.replied2015-05-17
dc.description.note学位:管理学硕士
dc.description.note院系专业:管理学院_工商管理硕士(工商管理硕士)
dc.description.note学号:17920121150831


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record